Compugen
Holon · 1 known investors
Find your way into Compugen
322 people in our graph share verified history with the Compugen team — schools, employers, funds. One of them is your warm intro.
Arnon Dinurunlockedknows Zurit Levine · together at Tel Aviv University (overlapped)
×8knows the team · via Tel Aviv University
×3knows the team · via Weizmann Institute of Science
Compugen develops immuno-oncology therapeutics using Unigen, a computational platform that combines scientific research with AI/ML to identify novel drug targets and design first-in-class antibody drugs. Its therapeutic antibodies targeting novel pathways are being evaluated in multiple clinical trials.
Founders & leadership
ZL
Zurit LevineinExecutiveZurit Levine holds degrees in biology and biochemistry from Tel Aviv University, including a Ph.D., and has worked at Compugen since 1999 in research and development roles of increasing seniority, currently serving as Senior Vice President of Strategic Collaborations responsible for partnerships and intellectual property strategy.
HA
Henry AdewoyeExecutive
JH
John HunterinExecutiveHe has over 25 years of experience in antibody and small molecule drug discovery and development, including leading teams that advanced multiple programs to IND filings.
AC
Anat Cohen-DayaginExecutiveAnat Cohen-Dayag holds a B.Sc. in Biology from Ben-Gurion University and an M.Sc. in Chemical Immunology and Ph.D. in Cellular Biology from the Weizmann Institute of Science. She has spent nearly 30 years in life sciences leadership, serving as President and CEO of Compugen for 15 years before becoming Executive Chair in September 2025, during which time she transformed the company from a computational biology service provider into a therapeutic development firm with an immuno-oncology pipeline and established partnerships with major pharmaceutical companies including AstraZeneca, Bayer, Bristol Myers Squibb, and Gilead.
KA
Kirk A. ChristofferseninExecutive
Board
AO
Arie OvadiaBoard director
GH
Gilead HalevyBoard director
PS
Paul SekhriBoard director
KL
Kinneret Livnat SavitzkyBoard director
YA
Yair AharonowitzBoard director
SZ
Sanford ZweifachBoard director
JB
Jean-Pierre BizzariBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$32M disclosed across 2 rounds · 2018–2021
▶$20MraisedNov 2021 · 1 investors · BiotechnologyRule 506(b)
▶$20MraisedNov 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Zurit LevineExecutive Officer
- Yaron TurpazExecutive Officer
- Anat Cohen-DayagExecutive Officer, Director
- Sanford ZweifachDirector
- Eran PerryDirector
- Jean-Pierre BizzariDirector
- Kinneret Livnat SavitzkyDirector
- Paul SekhriDirector
- Gilead HalevyDirector
- Oliver FroescheisExecutive Officer
- Henry AdewoyeExecutive Officer
- Ari KrashinExecutive Officer
- Offering amount
- $20M
- Amount sold
- $20M
- First sale
- Nov 2021
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
▶$12MraisedOct 2018 · 1 investors · OtherRule 506(b)
▶$12MraisedOct 2018 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Arie OvadiaDirector
- Zurit LevineExecutive Officer
- Gilead HalevyDirector
- Paul SekhriDirector
- Henry AdewoyeExecutive Officer
- Kinneret Livnat SavitzkyDirector
- Yair AharonowitzDirector
- John HunterExecutive Officer
- Anat Cohen-DayagExecutive Officer, Director
- Kirk A. ChristoffersenExecutive Officer
- Sanford ZweifachDirector
- Jean-Pierre BizzariDirector
- Ari KrashinExecutive Officer
- Offering amount
- $12M
- Amount sold
- $12M
- First sale
- Oct 2018
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Compugen Participates in H.C. Wainwright Investment - CGENbiopharmawatch.com · Sep 2026Frequently asked questions
- What does Compugen do?
- Compugen develops immuno-oncology therapeutics using Unigen, a computational platform that combines scientific research with AI/ML to identify novel drug targets and design first-in-class antibody drugs. Its therapeutic antibodies targeting novel pathways are being evaluated in multiple clinical trials.
- Who are Compugen's investors?
- Compugen's investors include Crescendo Venture Partners.
- How much funding has Compugen raised?
- Compugen has disclosed $32M raised across 2 rounds.
- Where is Compugen headquartered?
- Compugen is headquartered in Holon.